Correction of a pathogenic gene mutation in human embryos
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos as well 110-113 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [112]
In the citing paper
“Of the studies that have been conducted, the reported efficiencies of repair with templates in human embryos are very low (5,7,8).”
From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Orthwein, A. et al. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344, 189–193 (2014)”
Cited work 10.1126/science.1248024 · retracted 2025-01-09 · notice 10.1126/science.adv1263 · this paper published 2017-08
Citations
Cites
1 retracted
Mitosis Inhibits DNA Double-Strand Break Repair to Guard Against Telomere Fusions
Orthwein, A., Fradet-Turcotte, A., Noordermeer, S. M., Canny, M. D., Brun, C. M., Strecker, J., Escribano-Diaz, C., & Durocher, D. (2014) · Science · doi:10.1126/science.1248024 · Cited by 319
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Cited by
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
Leibowitz, M. L., Papathanasiou, S., Doerfler, P. A., Blaine, L. J., Sun, L., Yao, Y., Zhang, C.-Z., Weiss, M. J., & Pellman, D. (2021) · Nature Genetics · doi:10.1038/s41588-021-00838-7 · Cited by 583
“These findings provide potential mechanisms for the recently observed large chromosomal deletions or loss of heterozygosity surrounding on-target DSBs following genome editing in embryos 23,25,55,68,69 .”
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 581
Directed evolution of CRISPR-Cas9 to increase its specificity
Lee, J. K., Jeong, E., Lee, J., Jung, M., Shin, E., Kim, Y.-H., Lee, K., Jung, I., Kim, D., Kim, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05477-x · Cited by 525
Self-citationRegulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
“Although gene editing has brought many challenges, including miss target effect and induction of adaptive immune response, recent progress shows hope in reducing these results.(188,430) There is no doubt that gene editing Regulating tumor suppressor genes: post-translational modifications Chen et al.”
BackgroundTreatment of a metabolic liver disease by in vivo genome base editing in adult mice
Villiger, L., Grisch-Chan, H. M., Lindsay, H., Ringnalda, F., Pogliano, C. B., Allegri, G., Fingerhut, R., Häberle, J., Matos, J., Robinson, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0209-1 · Cited by 429
Genome editing reveals a role for OCT4 in human embryogenesis
Fogarty, N. M. E., McCarthy, A., Snijders, K. E., Powell, B. E., Kubikova, N., Blakeley, P., Lea, R., Elder, K., Wamaitha, S. E., Kim, D., et al. (2017) · Nature · doi:10.1038/nature24033 · Cited by 392
Self-citationLarge deletions induced by Cas9 cleavage
Adikusuma, F., Piltz, S., Corbett, M. A., Turvey, M., McColl, S. R., Helbig, K. J., Beard, M. R., Hughes, J., Pomerantz, R. T., & Thomas, P. Q. (2018) · Nature · doi:10.1038/s41586-018-0380-z · Cited by 371
Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges
Bagno, L., Hatzistergos, K. E., Balkan, W., & Hare, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.009 · Cited by 337
“Finally, recent advances in the development of high-precision genome-engineering tools, such as the CRISPR/ Cas system,(11) have introduced the possibility of using gene therapy to permanently edit and correct disease-causing mutations in the genome of adult cardiomyocytes.(12,13) However, despite the great promise, m…”
BackgroundCRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Marijon, E., Narayanan, K., Smith, K., Barra, S., Basso, C., Blom, M. T., Crotti, L., D'Avila, A., Deo, R., Dumas, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00875-9 · Cited by 313
Allele-Specific Chromosome Removal after Cas9 Cleavage in Human Embryos
Zuccaro, M. V., Xu, J., Mitchell, C., Marin, D., Zimmerman, R., Rana, B., Weinstein, E., King, R. T., Palmerola, K. L., Smith, M. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.025 · Cited by 303
Niederberger, C., Pellicer, A., Cohen, J., Gardner, D. K., Palermo, G. D., O’Neill, C. L., Chow, S., Rosenwaks, Z., Cobo, A., Swain, J. E., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.06.005 · Cited by 301
Self-citationNidhi, S., Anand, U., Oleksak, P., Tripathi, P., Lal, J. A., Thomas, G., Kuca, K., & Tripathi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073327 · Cited by 276
Kim, D. Y., Lee, J. M., Moon, S. B., Chin, H. J., Park, S., Lim, Y., Kim, D., Koo, T., Ko, J.-H., & Kim, Y.-S. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01009-z · Cited by 274
Self-citationMosaicism in CRISPR/Cas9-mediated genome editing
Mehravar, M., Shirazi, A., Nazari, M., & Banan, M. (2019) · Developmental Biology · doi:10.1016/j.ydbio.2018.10.008 · Cited by 272
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
Park, H., Oh, J., Shim, G., Cho, B., Chang, Y., Kim, S., Baek, S., Kim, H., Shin, J., Choi, H., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0352-0 · Cited by 272
Self-citationLong, C., Li, H., Tiburcy, M., Rodriguez-Caycedo, C., Kyrychenko, V., Zhou, H., Zhang, Y., Min, Y.-L., Shelton, J. M., Mammen, P. P. A., et al. (2018) · Science Advances · doi:10.1126/sciadv.aap9004 · Cited by 258
Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos
Alanis-Lobato, G., Zohren, J., McCarthy, A., Fogarty, N. M. E., Kubikova, N., Hardman, E., Greco, M., Wells, D., Turner, J. M. A., & Niakan, K. K. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004832117 · Cited by 234
CRISPR RNAs Trigger Innate Immune Responses in Human Cells
Kim, S., Koo, T., Jee, H.-G., Cho, H.-Y., Lee, G., Lim, D.-G., Shin, H. S., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.231936.117 · Cited by 222
Self-citationDeconstructing and reconstructing the mouse and human early embryo
Shahbazi, M. N., & Zernicka-Goetz, M. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0144-x · Cited by 228
Complete human day 14 post-implantation embryo models from naive ES cells
Oldak, B., Wildschutz, E., Bondarenko, V., Comar, M.-Y., Zhao, C., Aguilera-Castrejon, A., Tarazi, S., Viukov, S., Pham, T. X. A., Ashouokhi, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06604-5 · Cited by 226
Clemente-Suárez, V., Redondo-Flórez, L., Beltrán-Velasco, A., Ramos-Campo, D., Belinchón-deMiguel, P., Martinez-Guardado, I., Dalamitros, A., Yáñez-Sepúlveda, R., Martín-Rodríguez, A., & Tornero-Aguilera, J. (2023) · Biomedicines · doi:10.3390/biomedicines11092488 · Cited by 219
Managing Bardet–Biedl Syndrome—Now and in the Future
Forsythe, E., Kenny, J., Bacchelli, C., & Beales, P. L. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00023 · Cited by 215
“Initial reports of successful gene editing in humans include gene editing on embryos at risk for hypertrophic cardiomyopathy caused by MYBPC3 mutation (75) and treatment-resistant leukemia (75, 76).”
BackgroundCorrection of β-thalassemia mutant by base editor in human embryos
Liang, P., Ding, C., Sun, H., Xie, X., Xu, Y., Zhang, X., Sun, Y., Xiong, Y., Ma, W., Liu, Y., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0475-6 · Cited by 216
“In a recent report, it was found that diploid human zygotes, distinct from pluripotent cells, tends to repair DNA double strand break (DSB) using endogenous homologous sequence (Ma et al., 2017), consistent with what we have found in human tripronuclear zygotes (Liang et al.”
BackgroundMethodInfluentialCRISPR-based genome editing through the lens of DNA repair
Nambiar, T. S., Baudrier, L., Billon, P., & Ciccia, A. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.026 · Cited by 208
CRISPR‐Cas Biochemistry and CRISPR‐Based Molecular Diagnostics
Weng, Z., You, Z., Yang, J., Mohammad, N., Lin, M., Wei, Q., Gao, X., & Zhang, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202214987 · Cited by 203
Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy
Maron, B. J., Rowin, E. J., Udelson, J. E., & Maron, M. S. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.09.011 · Cited by 200
In vivo prime editing of a metabolic liver disease in mice
Böck, D., Rothgangl, T., Villiger, L., Schmidheini, L., Matsushita, M., Mathis, N., Ioannidi, E., Rimann, N., Grisch-Chan, H. M., Kreutzer, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9238 · Cited by 198
Hypertrophic Cardiomyopathy: The Future of Treatment
Tuohy, C. V., Kaul, S., Song, H. K., Nazer, B., & Heitner, S. B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1715 · Cited by 194
Self-citationGene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
The road ahead in genetics and genomics
McGuire, A. L., Gabriel, S., Tishkoff, S. A., Wonkam, A., Chakravarti, A., Furlong, E. E. M., Treutlein, B., Meissner, A., Chang, H. Y., López-Bigas, N., et al. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0272-6 · Cited by 188
Self-citationOff-target predictions in CRISPR-Cas9 gene editing using deep learning
Lin, J., & Wong, K.-C. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty554 · Cited by 185
PTEN-opathies: from biological insights to evidence-based precision medicine
Yehia, L., Ngeow, J., & Eng, C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121277 · Cited by 179
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 181
“For one of these studies (Ma et al., 2017), an active dialog is currently underway regarding the interpretation of the editing results (Adikusuma et al.”
BackgroundMethodSystematic identification of silencers in human cells
Pang, B., & Snyder, M. P. (2020) · Nature Genetics · doi:10.1038/s41588-020-0578-5 · Cited by 172
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171
Self-citationCarlson-Stevermer, J., Abdeen, A. A., Kohlenberg, L., Goedland, M., Molugu, K., Lou, M., & Saha, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01875-9 · Cited by 170
Rapid Quantitative Evaluation of CRISPR Genome Editing by TIDE and TIDER
Brinkman, E. K., & van Steensel, B. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9170-9_3 · Cited by 165
Stem-cell-based embryo models for fundamental research and translation
Fu, J., Warmflash, A., & Lutolf, M. P. (2021) · Nature Materials · doi:10.1038/s41563-020-00829-9 · Cited by 162
Tild-CRISPR Allows for Efficient and Precise Gene Knockin in Mouse and Human Cells
Yao, X., Zhang, M., Wang, X., Ying, W., Hu, X., Dai, P., Meng, F., Shi, L., Sun, Y. W., Yao, N., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.04.021 · Cited by 158
Self-citationEnhancement of target specificity of CRISPR–Cas12a by using a chimeric DNA–RNA guide
Kim, H., Lee, W.-J., Oh, Y., Kang, S.-H., Hur, J. K., Lee, H., Song, W., Lim, K. S., Park, Y., Song, B., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa605 · Cited by 161
“This novel system is advantageous in terms of safety and has application potential for various purposes in vivo (22,23), and will eventually be useful for gene therapy for diseases caused by genetic defects.”
BackgroundSelf-citationGene Therapy for the Heart Lessons Learned and Future Perspectives
Cannata, A. N., Ali, H., Sinagra, G., & Giacca, M. (2020) · Circulation Research · doi:10.1161/circresaha.120.315855 · Cited by 161
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
The CRISPR-baby scandal: what’s next for human gene-editing
Cyranoski, D. (2019) · Nature · doi:10.1038/d41586-019-00673-1 · Cited by 165
Zeng, Y., Li, J., Li, G., Huang, S., Yu, W., Zhang, Y., Chen, D., Chen, J., Liu, J., & Huang, X. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.007 · Cited by 148
“Moreover, recent successes in precise genome editing trials in early human embryos have suggested a potentially true cure for genetic diseases.(6,7) However, genome editing of human embryos caused huge concerns because of ethical issues and technical uncertainties regarding the efficiency and”
BackgroundDo CRISPR Germline Ethics Statements Cut It?
Brokowski, C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0024 · Cited by 96
“groups in China and were followed by a major study from Shoukrat Mitalipov and colleagues in Nature in August 2017, which reported the successful correction of a defective gene in human embryos.(9)”
BackgroundDetection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing
Weisheit, I., Kroeger, J. A., Malik, R., Klimmt, J., Crusius, D., Dannert, A., Dichgans, M., & Paquet, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107689 · Cited by 125
Regulated cell death pathways in cardiomyopathy
Sheng, S., Li, J., Hu, X., & Wang, Y. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01068-9 · Cited by 143
Glucocorticoid Signaling in Health and Disease: Insights From Tissue-Specific GR Knockout Mice
Whirledge, S., & DeFranco, D. B. (2018) · Endocrinology · doi:10.1210/en.2017-00728 · Cited by 126
CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
Memi, F., Ntokou, A., & Papangeli, I. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.003 · Cited by 154
CRISPR/Cas9‐mediated genome editing: From basic research to translational medicine
Jacinto, F. V., Link, W., & Ferreira, B. I. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14916 · Cited by 148
Hunt, J., Samson, C., du Rand, A., & Sheppard, H. M. (2023) · Human Genetics · doi:10.1007/s00439-023-02561-1 · Cited by 151
“(2020) used SNP genotyping and qPCR to demonstrate that LOH of SNP sites was due to a loss of DNA from chromosome arm truncations, as opposed to homology directed repair that was reported in a previous study (Ma et al. 2017).”
MethodOsteogenesis imperfecta and therapeutics
Morello, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.010 · Cited by 135
In utero gene editing for monogenic lung disease
Alapati, D., Zacharias, W. J., Hartman, H. A., Rossidis, A. C., Stratigis, J. D., Ahn, N. J., Coons, B., Zhou, S., Li, H., Singh, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8375 · Cited by 123
BE-PLUS: a new base editing tool with broadened editing window and enhanced fidelity
Jiang, W., Feng, S., Huang, S., Yu, W., Li, G., Yang, G., Liu, Y., Zhang, Y., Zhang, L., Hou, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0052-4 · Cited by 133
Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing
Mir, A., Alterman, J. F., Hassler, M. R., Debacker, A. J., Hudgens, E. D., Echeverria, D., Brodsky, M. H., Khvorova, A., Watts, J. K., & Sontheimer, E. J. (2018) · Nature Communications · doi:10.1038/s41467-018-05073-z · Cited by 131
In vitro–transcribed guide RNAs trigger an innate immune response via the RIG-I pathway
Wienert, B., Shin, J., Zelin, E., Pestal, K., & Corn, J. E. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2005840 · Cited by 119
A transatlantic perspective on 20 emerging issues in biological engineering
Wintle, B. C., Boehm, C. R., Rhodes, C., Molloy, J., Millett, P. D., Adam, L., Breitling, R., Carlson, R. H., Casagrande, R. J., Dando, M., et al. (2017) · eLife · doi:10.7554/elife.30247 · Cited by 134
“Genome engineering technologies like CRISPR/Cas9 offer the possibility to improve human lifespans and health, recently being shown in human embryos to repair disease-causing mutations (Ma et al., 2017).”
BackgroundCardiovascular Precision Medicine in the Genomics Era
Dainis, A., & Ashley, E. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.003 · Cited by 134
“A paper published in August 2017 described CRISPR editing of an HCM-associated MYBPC3 (cardiac myosin binding protein C) allele by co-injecting a CRISPR construct with sperm from a patient with a heterozygous MYBPC3 deletion into healthy donor eggs (58).”
BackgroundCRISPR Modeling and Correction of Cardiovascular Disease
Liu, N., & Olson, E. N. (2022) · Circulation Research · doi:10.1161/circresaha.122.320496 · Cited by 117
CRISPR/Cas approach: A new way of looking at plant-abiotic interactions
Mushtaq, M., Bhat, J. A., Mir, Z. A., Sakina, A., Ali, S., Singh, A. K., Tyagi, A., Salgotra, R. K., Dar, A. A., & Bhat, R. (2018) · Journal of Plant Physiology · doi:10.1016/j.jplph.2018.04.001 · Cited by 120
Inter-homologue repair in fertilized human eggs?
Egli, D., Zuccaro, M. V., Kosicki, M., Church, G. M., Bradley, A., & Jasin, M. (2018) · Nature · doi:10.1038/s41586-018-0379-5 · Cited by 111
Cecchino, G. N., Seli, E. U., Motta, E. L. A., & García-Velasco, J. A. (2018) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2018.02.007 · Cited by 122
The Future of IVF: The New Normal in Human Reproduction
Kushnir, V. A., Smith, G. D., & Adashi, E. Y. (2022) · Reproductive Sciences · doi:10.1007/s43032-021-00829-3 · Cited by 133
“Indeed, GGM has already been achieved in human embryos [80].”
BackgroundSherkatghanad, Z., Abdar, M., Charlier, J., & Makarenkov, V. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad131 · Cited by 129
Precision genome engineering through adenine and cytosine base editing
Kim, J. (2018) · Nature Plants · doi:10.1038/s41477-018-0115-z · Cited by 116
Self-citationCardiac Disorders and Pathophysiology of Sarcomeric Proteins
van der Velden, J., & Stienen, G. J. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00040.2017 · Cited by 124
“Direct correction of a heterozygous mutation in MYBPC3 was established in human embryos using CRISPR/Cas9 technology (256).”
MethodAdvancements and Obstacles of CRISPR-Cas9 Technology in Translational Research
You, L., Tong, R., Li, M., Liu, Y., Xue, J., & Lü, Y. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.02.008 · Cited by 128
“2%, and embryos exhibited no mosaicism, no off-target gene editing, and no other abnormalities.(49) Moreover, embryos preferred the gene copies of the healthy parent to that of an exogenous DNA donor as a repair template.”
BackgroundLin, J., Zhang, Z., Zhang, S., Chen, J., & Wong, K. (2020) · Advanced Science · doi:10.1002/advs.201903562 · Cited by 101
Molecular biology at the cutting edge: A review on CRISPR/CAS9 gene editing for undergraduates
Thurtle‐Schmidt, D. M., & Lo, T. (2018) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.21108 · Cited by 103
“[53], successfully edited embryos that were heterozygous for a mutation in the MYBPC3 gene using CRISPR/Cas9.”
MethodCommensal Koch's postulates: establishing causation in human microbiota research
Neville, B. A., Forster, S. C., & Lawley, T. D. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.10.001 · Cited by 102
“Despite the promise of CRISPR-Cas9 systems [55] we currently lack clinically-ready tools to manipulate the human genome.”
BackgroundGene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G.-S. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 100
“Initial success was indeed achieved in a study where the CRISPR/SpCas9 system was used to efficiently correct a mutation in the MYBPC3 gene related to hypertrophic cardiomyopathy in viable human embryos (Ma et al., 2017).”
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 99
on behalf of the European Society of Human Reproduction and Embryology and European Society of Human Genetics, Harper, J. C., Aittomäki, K., Borry, P., Cornel, M. C., de Wert, G. M. W. R., Dondorp, W., Geraedts, J. P. M., Gianaroli, L., Ketterson, K., et al. (2017) · European Journal of Human Genetics · doi:10.1038/s41431-017-0016-z · Cited by 125
“documented in the case of hypertrophic cardiomyopathy [217].”
BackgroundOptimizing Precision Medicine for Public Health
Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G. S., & Nowak, K. J. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00042 · Cited by 105
“However, the first description of CRISPR-Cas9 gene technology used to correct human embryos (41) with genetic mutations causative of hypertrophic cardiomyopathy has been controversial (42).”
BackgroundComprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption
Xin, C., Yin, J., Yuan, S., Ou, L., Liu, M., Zhang, W., & Hu, J. (2022) · Nature Communications · doi:10.1038/s41467-022-33346-1 · Cited by 110
Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications
Patel, S., Athirasala, A., Menezes, P. P., Ashwanikumar, N., Zou, T., Sahay, G., & Bertassoni, L. E. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0444 · Cited by 98
“Microinjection, yet another physical method, makes use of a microneedle to inject mRNA into individual cells.(68,69) The low throughput of this technique makes it extremely labor intensive and hence, has only seen sporadic use.”
MethodPrecision Medicine in the Management of Dilated Cardiomyopathy
Fatkin, D., Huttner, I. G., Kovacic, J. C., Seidman, J. G., & Seidman, C. E. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.011 · Cited by 103
Gene Editing of Microalgae: Scientific Progress and Regulatory Challenges in Europe
Spicer, A., & Molnar, A. (2018) · Biology · doi:10.3390/biology7010021 · Cited by 97
Kimberland, M. L., Hou, W., Alfonso-Pecchio, A. R., Wilson, S., Rao, Y., Zhang, S., & Lu, Q. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.08.007 · Cited by 109
Strategies to reduce genetic mosaicism following CRISPR-mediated genome edition in bovine embryos
Lamas‐Toranzo, I., Galiano-Cogolludo, B., Cornudella-Ardiaca, F., Cobos-Figueroa, J., Ousinde, O., & Bermejo‐Álvarez, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-51366-8 · Cited by 103
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 114
“Recently, a breakthrough was made in human embryos.(504) Mutations in the thick filament-associated cardiac myosinbinding protein C (MYBPC3) gene account for approximately 40% of all genetic defects in hypertrophic cardiomyopathy.”
BackgroundThe Promise and Challenge of In Vivo Delivery for Genome Therapeutics
Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 102
Genome Editing: Past, Present, and Future.
Carroll, D. (2017) · PubMed Central · Cited by 191
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 102
Musson, R., Gąsior, Ł., Bisogno, S., & Ptak, G. (2022) · Human Reproduction Update · doi:10.1093/humupd/dmab046 · Cited by 106
“For example, DSBs in the male pronucleus are repaired mainly by HR using the female allele as a template (Ma et al. , 2017).”
Endogenous Fluorescence Tagging by CRISPR
Bukhari, H., & Müller, T. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.08.004 · Cited by 82
Engineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 81
Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy
Dubey, A. K., & Mostafavi, E. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1259435 · Cited by 103
CRISPR/Cas9 microinjection in oocytes disables pancreas development in sheep
Vilariño, M., Rashid, S. T., Suchy, F. P., McNabb, B. R., van der Meulen, T., Fine, E. J., Ahsan, S. D., Mursaliyev, N., Sebastiano, V., Diab, S. S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17805-0 · Cited by 88
Sperm–egg interaction and fertilization: past, present, and future
Okabe, M. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy028 · Cited by 94
Sport and exercise genomics: the FIMS 2019 consensus statement update
Tanisawa, K., Wang, G., Seto, J. T., Verdouka, I., Twycross-Lewis, R., Karanikolou, A., Tanaka, M., Börjesson, M., Luigi, L. D., Dohi, M., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2019-101532 · Cited by 96
Enabling large-scale genome editing at repetitive elements by reducing DNA nicking
Smith, C. J., Castanon, O., Said, K., Volf, V., Khoshakhlagh, P., Hornick, A., Ferreira, R., Wu, C., Güell, M., Garg, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa239 · Cited by 85
Metadata
- Authors
- Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., Darby, H., Van Dyken, C., Li, Y., Kang, E., Park, A.-R., Kim, D., Kim, S.-T., Gong, J., Gu, Y., Xu, X., Battaglia, D., Krieg, S. A., Lee, D. M., Wu, D. H., Wolf, D. P., Heitner, S. B., Belmonte, J. C. I., Amato, P., Kim, J.-S., Kaul, S., & Mitalipov, S.
- Affiliations
- Oregon Health & Science University (US)
- Institute for Basic Science (KR)
- Salk Institute for Biological Studies (US)
- Seoul National University (KR)
- BGI Group (China) (CN)
- Corresponding author
- Amato, Paula
- Kim, Jin-Soo
- Kaul, Sanjiv
- Mitalipov, Shoukhrat
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7668
- Pages
- 413-419
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2740810575
- Cited by
- 992
- References
- 48
- Citations by year
- 2026: 22 · 2025: 50 · 2024: 47 · 2023: 93 · 2022: 75 · 2021: 107 · 2020: 135 · 2019: 155 · 2018: 217 · 2017: 88
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2017-10-02)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Oregon Health and Science University
- Leona M. and Harry B. Helmsley Charitable Trust
- Consorzio Interuniversitario Biotecnologie
- Moxie Foundation
- Government of Jiangxi Province
- Institute for Basic Science (IBSR021-D1, R021-D1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- germline editing, CRISPR/Cas9, MYBPC3 mutation, hypertrophic cardiomyopathy, preimplantation embryo, homology-directed repair, mosaicism, DNA double-strand break repair, cell cycle timing, preimplantation genetic diagnosis, off-target mutations
- MeSH terms
- Gene Editing, Myosin Binding Protein C, Adult, Alleles, Blastocyst, Carrier Proteins, Cell Division, Embryo, Mammalian, Genetic Complementation Test, Heterozygote, Homozygote, Humans, Male, Mosaicism, Mutation, Templates, Genetic, Zygote, S Phase, Gene Targeting, DNA Breaks, Double-Stranded, Recombinational DNA Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.